Each re-evaluation is achieved by balancing users’ a priori information with observed data. The observed part is weighted with respect to the amount of trial data already collected.
The re-evaluation mechanism also allows initializing a computation with all existing patients at their current status in the trial and all inventories with their actual amount of medication kits. Since future medication usage for patients already stratified and randomized
